Real World Predictors of Response and 24-month survival in

high-grade *TP53*-mutated Myeloid Neoplasms

Amandeep Kaur[1]*, Alexandra E. Rojek[2]*, Emily Symes[1], Anand A. Patel[2], Mariam
Nawas[2], Jay L. Patel[3], Payal Sojitra[4], Barina Aqil[5], Madina Sukhanova[5], Megan E.
McNerney[1], Leo Wu[1], Aibek Akmatbekov[1], Jeremy Segal[1], Melissa Tjota[1], Sandeep
Gurbuxani[1], Jason X. Cheng[1], Su-Yeon Yeon[6], Harini V. Ravisankar[1], Carrie Fitzpatrick[1],
Angela Lager[2], Michael W. Drazer[2], Caner Saygin[2], Pankhuri Wanjari[1], Panagiotis
Katsonis[7], Olivier Lichtarge[7], Jane E. Churpek[8], Sharmila B. Ghosh[9], Ami B. Patel[3],
Madhu P. Menon[3], Daniel A. Arber[1], Peng Wang[1*], & Girish Venkataraman[1*]

11
[1]Department of Pathology, Sections of Hematopathology & Genomic Pathology, University of
Chicago Medicine, Chicago, IL
[2]Hematology/Oncology Department of Medicine, University of Chicago Medicine, Chicago, IL
[3]Departments of Pathology and Hematology/Oncology, University of Utah/ARUP, UT
[4]Department of Pathology, Rutgers Robert Wood Johnson Medical School New Brunswick NJ
[5]Department of Pathology, Northwestern Memorial Hospital, Chicago, IL
[6]Department of Pathology, University of Illinois, Chicago, IL
[7]Molecular and Human Genetics, Baylor College of Medicine, TX
[8]Department of Medicine, Division of Hematology, University of Wisconsin, Madison, WI
[9]Department of Pathology, Henry Ford Health Systems, Detroit, MI
22
23
24   * Equal authorship

25
26   **Word Count   : 4005**
27   **No. of Figures: 5**
28   **No. Tables   : 2**
29   **Supp. Figures: 10**
30
31   **Running Title: *Outcomes in TP53-mutated Myeloid Neoplasm***
32
33   **Key Points:**
34   * ≥2 monosomies, multi-hit *TP53* allelic state & *CUX1* deletions are associated with poor
35   frontline response in *TP53*-mutated myeloid neoplasm.
36   * *TP53* VAF>25% and co-alterations in any one of six genes (*CBL, CUX1, EZH2, KRAS,*
37   *TET2 & U2AF1*) adversely impact 24-month survival.
38
39   **Keywords:** *TP53*, karyotype, monosomy, acute myeloid leukemia, outcomes, mutations, *CUX1*.
40

Contact:
Girish Venkataraman, M.D.
Professor of Hematopathology
Department of Pathology
TW-055B, MC 0008

The University of Chicago Medicine
5841 S. Maryland Avenue
Chicago, IL 60637
Phone: 773-702-6196
Fax: 773-702-9207
girish.venkataraman@uchospitals.edu
52

1 ABSTRACT

Current therapies for high-grade *TP53*-mutated myeloid neoplasms (≥ 10% blasts) do not offer a

meaningful survival benefit except allogeneic stem cell transplantation in the minority who

achieve a complete response to first line therapy (CR1). To identify reliable pre-therapy

predictors of response and outcomes, we assembled a cohort of 234 individuals with well-

annotated clinical, molecular and pathology data, evaluating CR1 & 24-month survival (OS24).

In this elderly cohort (median age 68.0 years) with 73.4% receiving frontline non-intensive

regimens (hypomethylating agents with or without venetoclax), we identified several novel

factors predictive of inferior CR1 including male gender (P = .019), ≥ 2 autosomal monosomies

(P < .001), -17/17p (P = .008), multi-hit *TP53* allelic state (P < .001) and *CUX1* alterations (P =

.009). Inferior OS24 was predicated by ≥ 2 monosomies (P = .004), *TP53* VAF>25% (P < .001),

and *TP53* splice junction mutations (P = .007). In addition, mutations/deletions in any of six

genes including *CUX1*, *U2AF1*, epigenetic regulators (*EZH2*, *TET2*), or *RAS* pathway genes

(*CBL*, *KRAS*) (termed '*EPI6*' signature) predicted inferior OS24 (HR = 2.0 [1.5–2.8]; *P* < .0001).

A risk score incorporating these accessible binary factors in a multivariable model stratified 3

prognostic distinct groups: favorable, intermediate, and poor with significantly different median

(15.4, 9.2, 3.5 months) and 24-month (48.4%, 14.3%, 0.5%) survival (OS24) (P < .0001). For

the first time, in a seemingly monolithic high-risk cohort, our data provides means to tease out

small subgroups at baseline with superior or very poor outcomes.

INTRODUCTION

Several studies in the past decade have confirmed the adverse outcome of complex and monosomal karyotype as well as *TP53* alterations in the context of myeloid neoplasms (MN).[1-4] *TP53**MUT* MN are characterized by frequent complex karyotype (CK) and very poor 2-year survival of 12.8%, regardless of blast count.[5] Based on these studies, high-risk myelodysplastic syndrome (MDS) including MDS/AML (MDS/AML) and AML with mutated *TP53* (*TP53**MUT*) are now recognized as distinct categories in the World Health Organization 5th edition (WHO5), International Consensus Classification of hematopoietic neoplasms (ICC), and European LeukemiaNet (ELN) risk stratification.[6-9]

Beyond assessing complete response to first-line therapy (CR1) and allogeneic hematopoietic stem cell transplantation (allo-SCT) in CR1, there are no well-established pre-therapy prognostic indicators in this cohort of patients[10] who are automatically assigned to the adverse group per ELN2022 risk stratification.[9] Furthermore, there is a significant heterogeneity in responses to available therapies (intensive chemotherapy *vs.* hypomethylating agent (HMA)-based therapy) or agents used in clinical trials (for e.g. APR-246[11]) with few long-term survivors even in those receiving allo-SCT.[12] Consequently, there is a pressing need to explore better means to identify disease characteristics influencing therapeutic response to optimally select frontline treatments and identify patients who are likely to achieve durable benefit from allo-SCT in CR1.

With this background, in this study we asked if 1) specific chromosomal alterations within a CK (such as autosomal monosomies), 2) the type of *TP53* mutation (missense [*TP53**MIS*] *vs.* non-

44   missense *TP53* mutations [*TP53*^{NMIS}]), and 3) patterns of co-mutations/alterations contribute

45   additional prognostic value beyond *TP53* allelic state in risk-stratifying *TP53*^{MUT} MN.

MATERIALS AND METHODS

Cohort Case Selection and Sample Procurement

We identified patients with $TP53^{MUT}$ MN carrying $\geq$ 1 *TP53* mutation at a VAF $\geq$ 3% diagnosed between 2014-2023 across four US centers with largely similar treatment practices. We excluded individuals with any of the following: a known germline *TP53* mutation, known $TP53^{MUT}$ precursor states (CHIP, CCUS), MDS with mutated *TP53* (< 10% blasts) [6], and core binding factor-altered AMLs.

Data Collection: We collected data on demographics, marrow pathology, molecular and cytogenetic information, and treatment types. Therapies were categorized as: **1]** Intensive Chemotherapy (IC) (7+3 or high-dose cytarabine), **2]** Hypomethylating agent (HMA)-based (without venetoclax), **3]** HMA-based with venetoclax, or **4]** Best supportive care/palliative regimens. Response was assessed per ELN 2017 guidelines[13] denoting both CR and CR with incomplete hematologic recovery (CRi) as a composite measure of CR1.

Cytogenetic studies

Chromosome analysis was performed following standard cytogenetic laboratory clinical protocol. Fluorescence in situ hybridization (FISH) testing was performed using probe sets targeting most recurring abnormalities in myeloid neoplasms on bone marrow or malignancy-involved peripheral blood. Using previously published criteria, over 90% of the cohort cases met the classification of monosomal karyotype (MK).[1] Therefore, we applied a revised definition of

68   MK restricting to only unique autosomal monosomies (0-1 *vs.* 2+) without considering other

69   structural alterations (**supplemental S1**).

Next Generation Sequencing

Somatic next-generation sequencing (NGS) data was available in all cases. To maintain

consistency in our analysis, we only included genes that were tested across two or more

centers (**supplemental S2**). For missense *TP53* mutations, we also examined the evolutionary

action score for p53 (**supplemental S3**).[14] Additionally, germline testing data (**supplemental**

S4) was available in a subset of cases.

Allelic status: *TP53* multi-hit (*TP53^{MH}*) allelic state was designated per ICC 2022 schema.[6]

However, single-hit (*TP53^{SH}*) designation used an expanded VAF cutoff including cases with

VAF between 3-10%. Additionally, we modeled any non-missense *TP53* mutations (*TP53^{NMIS}*)

as a binary predictor.

Data analysis

The primary endpoint was 24-month overall survival (OS24) from the time of diagnosis of

TP53^{MUT} MN to death or last follow-up, censoring patients alive at 24 months. Response to first-

line therapy was also evaluated. We employed non-parametric Kaplan-Meier methods, along

with Cox proportional hazards (P-H) regression models[15], and, where suitable, flexible

parametric models[16] (**supplemental S5**).

RESULTS

Cohort Summary

Table 1 depicts the baseline data of all patients comprising 102 (43.6%) females. Individuals

accrued after 2018 were significantly older with 47.7% surpassing 70 years of age as opposed

to 29.0% in the pre-2018 period (P = .011). Additionally, post-2018 individuals frequently

received lower-intensity therapies including HMA+/-venetoclax or CPX-351. Furthermore,

individuals with AML (blasts ≥ 20%) were significantly more likely to receive VEN-based

regimens compared to patients with MDS/AMLs (P = .003) at diagnosis.

Most patients (81.0%; 170/210) exhibited complex karyotypes characterized by frequent

autosomal monosomies (83.8%; 176/210) along with several recurrent balanced and

unbalanced structural alterations in 93.3% of cases (**Figure 1** ideogram). The two most

prevalent single autosomal monosomies affected chromosomes 17 in 33.3% (70/210) and 7 in

31.0% (65/210) (**Supplemental Figure 1** for co-occurrence plot). There was no association

between *TP53* allelic state and prior cytotoxic-therapy (P = .20). Among germline alterations,

BRCA1, *BRCA2* and *DDX41* alterations predominated.

$TP53^{NMIS}$ mutations are frequently associated with multi-hit allelic state and

autosomal monosomies

Mutational analysis identified 294 pathogenic mutations (193 unique mutations) among the 235

patients comprising mostly hot-spot DNA-binding domain $TP53^{MIS}$ mutations (**Supplemental**

Figure 2). A total of 30.2% (71/235) harbored non-missense *TP53* mutations, either singly or as

part of multiple *TP53* mutations. Individuals with single *TP53* mutations were significantly more

likely to harbor loss of chromosome 17p either due to monosomy 17 or structural losses of 17p

(46.5% *vs.* 27.8% in multiple *TP53* mutations; P = .016). Among $TP53^{NMIS}$ mutations, splice

junction mutations ($TP53^{sjm}$) occurring in 22 (9.4%) were marginally more prevalent in men (P =

.040).

The median *TP53* VAF was 42% (IQR: 23–59%). and did not differ between $TP53^{MIS}$ and

$TP53^{NMIS}$ alterations (*P* = .83). Sub-clonal *TP53* mutations (VAF < 10%) were observed in 6.8%

(16/235) with single mutations and 4.3% (10/235) with 1+ mutations. $TP53^{NMIS}$ were more

frequently associated with ≥ 2 monosomies (75.0% *vs.* 55.8% in $TP53^{MIS}$; *P* = .006),

chromosome 7 losses (65.8% *vs.* 45.4% in $TP53^{MIS}$; *P* = .005), multiple *TP53* mutations (42.0%

vs. 15.0% in $TP53^{MIS}$; *P* < .0001) and germline alterations (33.3% *vs.* 10.9% with germline in

$TP53^{MIS}$; *P* = .022). Patients with $TP53^{MIS}$ EAp53 score in upper quartile (*N* = 96/134) frequently

had *TP53* VAF > 25% (87.2% *vs.* 71.6%*; P* = .032).

A 6-gene co-alteration signature including *CUX1* deletion is associated with higher *TP53* VAF

Co-alterations were present in 62.4% (*N* = 146) with a median of 1 co-alteration (range: 0–16

co-alteration). Co-alterations in epigenetic pathways (*DNMT3A* and *TET2*) genes predominated

(**Figure 2**), in line with prior observations.[5] Males had a higher frequency of mutations in genes

of the spliceosome complex (*SF3B1*, *SRSF2*, *U2AF1* or *ZRSR2*) (18.9% *vs.* 5.9% in females; *P*

= .003) and the nine myelodysplasia-related genes[6] (31.8% *vs.* 18.6% in females; *P* = .023).

Among structural alterations detected by NGS, losses at the *CUX1* locus occurring in 10.0%

(22/220) of individuals were the most frequent structural alteration (after losses at the *TP53*

locus). Patients with any co-alteration had a significantly higher median *TP53* VAF (45.6% *vs.*

42.1%; *P* = .014). Likewise, individuals carrying *CUX1*-alterations had almost double the *TP53*

VAF compared to those without *CUX1* alterations (78.5% *vs.* 43%; *P* < .0001).

We constructed an '*EPI6*' signature based on alterations co-occurring in ≥ 4 individuals and

defined by the presence of mutations or deletions in at least one of six key genes associated

with methylation (*TET2*, *EZH2*), mitogen-activated protein kinase (*KRAS*), signaling (*CBL*),

splicing (*U2AF1*) pathways or *CUX1*. We selected these genes based on their frequency of

occurrence and impact in initial exploratory univariable analysis. This *EPI6* signature was

present in 25.6% (60/234) of individuals with a significantly higher proportion harboring *TP53*

VAF > 25% (88.3% *vs.* 73.6% with VAF > 25% in individuals lacking *EPI6*; *P* = .018). We used

this *EPI6* signature going forward in our analyses of treatment outcomes and long-term survival.

Response data: *CUX1* alterations and ≥ 2 autosomal monosomies predict inferior CR1

First-line response was evaluable in 190 patients with 27.4% achieving CR, 21.6% with partial

response, and 51.1% with non-response/stable-progressive disease. There was no difference in

CR rates between lower-intensity (30.8%; *N* = 36/117) and intensive regimens (27.1%; *N*

=13/48, *P* = .64). although surprisingly, CR rates were higher in females (36.2% *vs.* 20.9% CR1

in Male; *P* = .019).

The biological predictors of inferior CR1 were ≥ 2 monosomies (17.1% *vs.* 42.9% CR1 in 0-1

Monosomy; *P* < .001), losses on chromosome 17 (16.7% *vs.* 35.0%; *P* = .008), $TP53^{MH}$ allelic

state (20.0% *vs.* 45.5%; *P* < .001), myelodysplasia-related gene mutations (15.5% *vs.* 32.6%; *P*

= .015) as well as *EPI6* (16.7% *vs.* 31.0%; *P* = .054). Remarkably, none of the individuals with

CUX1 alterations achieved a CR (0.0%; 0/18) *vs.* 45/159 (28.3%) CR1 without *CUX1*

alterations. Chromosome 5 (*P* = .65) and chromosome 7 losses (*P* = .52) did not impact

frontline response.

Among lower-intensity HMA-based regimens, HMA+VEN did not result in significantly higher

CR rates (35.9%) *vs.* 24.0% in HMA only (*P* = .17). These data are in line with several recent

reports.[17-20] However, among patients with blast counts over 20%, HMA+Ven resulted in

marginally higher CR rates (36.5% *vs.* 16.7% in HMA only; *P* = .06). In a multi-variable logistic

regression model including gender and the aforementioned biologic factors (*TP53* allelic state,

gender and *EPI6*), ≥ 2 monosomies (OR = 0.30 [95% CI: 0.14–0.65]; *P* = .002), *TP53* allelic

state (OR = 0.42 [95% CI: 0.19–0.93]; *P* = .032) predicted significantly inferior response with a

marginal effect for *EPI6* (*P* = .08) (**Supplemental Figure 4**, ROC curve).

Baseline outcome data

The median duration of follow up from diagnosis of $TP53^{MUT}$ MN to study exit was 6.5 months (range: 0.2–78.4 months) with 203 deaths in 234 patients and a death rate of 87.7 per 1000 patient-years with a 24-month survival of 15.7% (95% CI = 11.1–21.1%).

Uni-variable analyses of OS24

Age at diagnosis > 70 years (HR = 1.6 [1.2–2.1]; *P* = .002), antecedent treated myeloid neoplasm (HR = 1.8 [1.3–2.6]; *P* = .001; **Figure 3A**) and complex karyotype (HR = 1.7 [1.1–2.6]; *P* = .014) all predicted worse OS24. Blast count at diagnosis and prior cytotoxic therapy-related myeloid neoplasm did not influence outcomes. Among chromosomal alterations, del(7q) (HR = 1.5 [1.1–2.0]; *P* = .013) and monosomy of chromosomes 17 (HR = 1.4 [1.0–1.9]; *P* = .046) predicted inferior outcomes. Neither del(5q), del(17p), nor monosomies of 5 or 7 impacted survival. Comparing 0-1 *vs.* ≥ 2 monosomies, the latter group experienced significantly higher hazard of mortality (HR = 1.7 [1.2–2.3]; *P* = .002) (**Figure 3B**).

***TP53^NMIS^* but not multi-hit allelic state is adverse:** We next assessed different measures of *TP53* mutations and their associations with outcome. The number of *TP53* mutations (1 *vs.* 1+) did not impact OS24. Overall, $TP53^{NMIS}$ did not impact OS24, among individuals with single *TP53* mutations, $TP53^{NMIS}$ predicted significantly inferior median survival (4.0 *vs.* 9.2 mos.; $P_{Log-rank}$ = .025) with early mortality. Among $TP53^{NMIS}$, splice junction mutations were associated with particularly poor outcomes (HR = 1.9 [1.2–3.1]; *P* = .007) (**Figure 3C**). Neither underlying germline alterations (*P* = .40) nor $TP53^{MH}$ allelic state (*P* = .08) conferred worse outcomes.

While all *TP53* VAF cutoffs (>10%, >25%, >40%, and >50%) predicted inferior OS24, we selected VAF > 25% (HR = 1.9 [1.3–2.8]; *P* < .001) for all subsequent analysis based on the balance of cases across both groups for an appropriately powered analysis (**Figure 3D**). Intriguingly, the beneficial impact of a lower VAF within each of these binary cut-points were restricted only to male gender when examined separately by gender (**Supplemental Figure 3**) although the analysis was slightly underpowered.

***CUX1* deletions and *EPI6* signature including *CUX1* are both adverse:** The presence of any

co-alteration occurring in 146/234 (62.4%) did not impact survival (P = .63). *CUX1* alterations

(mostly losses detected by NGS) were associated with particular very poor survival (1.2% *vs.*

15.5%; P_{fpm} < .001) without any survivor beyond 12 months of diagnosis. Looking at

combinations of co-altered genes, co-alterations in myelodysplasia-related genes (P = .52) or

spliceosome complex genes did not impact survival (P = .95). In an age-adjusted model, *EPI6*

predicted significantly inferior OS24 (3.3% *vs.* 18.5% for no *EPI6*; P_{fpm} < .0001; HR = 2.0 [1.5–

2.8]; P < .0001 **Figure 4**) with a differential impact of each of *EPI6* genes when stratified by

gender (**Figure 4A**).

Venetoclax-based regimens do not offer significant survival benefit: Using low-intensity

therapies as a referent group, patients receiving intensive regimens (7+3 or HiDAC-based)

experienced slightly better outcomes in an age-adjusted analysis (HR = 0.6 [0.4–1.0]; P = .043;

N = 192) and OS24 (29.3% *vs.* 12.0% in low-intensity; P_{fpm} = .006). Among patients treated with

intensive chemotherapy (excluding patients treated with CPX-351), VAF > 25% (HR = 3.5 [1.3–

9.1]; P = .011; N = 51) and EAp53 score in the highest quartile (HR = 2.2 [1.0–4.8]; P = .06; N =

39) were both adverse. In a subgroup analysis by VAF, the beneficial effect of intensive

regimens over non-intensive regimens was restricted only to individuals with VAF ≤ 25%.

Among HMA-treated individuals, HMA+venetoclax regimens were marginally adverse in

patients older than 70 years (HR = 1.5 [0.9–2.7]; P = .15; N = 71) with no overall survival benefit

compared to HMA only, in line with recent data.[21] Within the HMA-treated subgroup (N = 137),

only *EPI6* predicted poor outcomes (HR = 1.7 [1.1–2.8]; P = .019; N = 137). Neither *TP53* allelic

status, VAF, nor EAp53 score (**Supplemental Figure 6**) were prognostic in this subgroup.

Additionally, we performed univariate Cox analyses for separate subgroups by therapy and

TP53 allelic state (**Supplemental Figure 7**). Achieving CR1 to first-line significantly improved

outcomes (OS24 40.5% *vs.* 7.3% for no CR1; P < .0001).

Allogeneic transplant and CR at day 100 post-alloSCT are favorable: A total of 37 (15.8%)

patients underwent alloSCT including nearly 50% of those who had achieved CR1 to prior first-

line therapy. Patients with monosomy 7, *TP53* VAF > 25% and $TP53^{MH}$ at diagnosis were

significantly less likely to undergo alloSCT (*P* = .017, *P* = .016, *P* = .027 respectively).

Transplanted individuals enjoyed significantly superior median survival (Not reached *vs.* 5.6

mos. for no alloSCT; $P_{Log\text{-}rank}$ < .0001) and OS24 (59.1% *vs.* 5.0% for no alloSCT; P_{fpm} < .0001).

Likewise, among transplanted individuals, ongoing CR at day +100 post-alloSCT was

significantly associated with better OS24 (64.1% *vs.* 37.5% for no CR; P_{fpm} = .045), in

congruence with the COMMAND study demonstrating significant beneficial impact of alloSCT in

$TP53^{MUT}$ MNs.[10] Early relapse by day+100 was significantly more likely in patients with an *EPI6*

signature present (*P* = .001), high EAp53 score (*P* = .028) with a marginal effect for *CUX1*

alterations (*P* = .08) at diagnosis.

TP53 Risk Score (*TP53*RS) for $TP53^{MUT}$ Myeloid Neoplasms

Based on the biologic predictors relevant in univariable analysis, we fitted a pre-therapy multi-

variable model including antecedent treated myeloid neoplasm, autosomal monosomies (0-1 *vs.*

2+), *TP53* VAF > 25%, *TP53* splice junction mutations, and *EPI6* signature adjusting for age.

The models include regular Cox, 45-day landmark Cox, and a competing risk model modeling

only leukemia-specific deaths in the competing risk model (See Table 2 for details) .

We then developed a novel *TP53* risk score (*TP53*RS) with the above four factors creating three

risk groups. These comprised favorable (0 factors, *TP53*RS0), intermediate (1-2 factors,

*TP53*RS1), and adverse (3+ factors, *TP53*RS2) groups with significantly different median

survival (15.4 *vs.* 9.2 *vs.* 3.5 mos.; $P_{Log\text{-}rank}$ < .0001) as well as 24-month survival (48.4% *vs.*

14.3% *vs.* 0.5%; P_{fpm} < .0001) respectively (**Figure 5A**).

Additional sensitivity analyses were performed to address: **1]** clustering of individuals across

centers, and **2]** heterogeneity of NGS testing methodology between centers. To address the

first, the Cox analysis included a clustering option while for the second, we restricted analysis to

a single institution with most patients undergoing uniform capture-based NGS testing. In both

analyses, *TP53*RS remained significant (HR = 2.7 [2.0–3.8]; *P* < .0001; *N* = 163; (**Figure 5B**))

albeit with a modest Harrell's *C* = 0.63 and explained variance (Somer's R²d statistic) of 22%

(95% CI: 11–33%). Much of the remaining variance in both models was explained by CR1 and

allo-SCT. Lastly, since inclusion of cases with *TP53* VAF < 10% could potentially inflate the

impact of the proposed score, we performed an additional sensitivity analysis excluding 18

(7.7%) such individuals. *TP53*RS retained its prognostic value in this last analysis as well (HR =

2.4 [1.7–3.2]; *P* < .0001; *N* = 195). Since the numbers of patients with *TP53* RS0 comprised less

than 10% of the cohort, a sensitivity analysis looking at its relevance separately in non-

intensively treated patients was underpowered and hence not undertaken.

External validation of *TP53*RS: We identified 135 patients with $TP53^{MUT}$ MNs reported by

Bernard et al[22] with blast count > 9%. Univariable analyses were conducted with monosomies,

VAF > 25%, *TP53* mutation class, and *EPI6* in younger and older patients (**Supplemental

Figure 8**). While *EPI6* did not separate outcomes in this cohort (**Supplemental Figure 9A**)

likely due to infrequent *CUX1* alterations (1 of 135) in the publicly available data, *TP53*RS

remained relevant (**Supplemental Figure 9B**).

DISCUSSION

Our study goes beyond merely affirming the adverse impact of any *TP53* mutations or their VAF in myeloid neoplasms and identifies several novel factors that reliably predict poor response to first-line therapy (monosomal karyotype, multi-hit *TP53* allelic state, *CUX1* deletions) and inferior survival including a novel *EPI6* co-alteration signature. The most remarkable aspect perhaps is the identification of these factors within an already high-risk cohort revealing small subgroups with either favorable or very poor outcomes.

Our data indicates that there is information gleaned beyond *TP53* VAF where *TP53* allelic state assessment as well as *TP53* mutation class (*TP53^{sjm}* vs. others) are both relevant for front-line response and/or survival. While the 25% *TP53* VAF cutoff in our study was admittedly data-driven, it was nevertheless in line with the 23% cutoff proposed by Bahaj and coworkers[23] as well as the 25% cutoff used by Grob and coworkers[5] although this latter study was an exclusively chemotherapy-treated, and slightly younger cohort. In comparing the impact of VAF by treatment subgroups, we note as well that *TP53* VAF is relevant only within the intensive chemotherapy treated subgroups, in line with prior studies.[17, 24] We were however surprised by the higher CR rates in females possibly attributable to less frequent *TP53^{MH}* in females. Whether additional fitness-related factors or better compliance in females play a role remains to be seen.

While *TP53* allelic state did not impact survival, it nevertheless remains useful in assessing response to front-line therapy (more so in patients receiving non-intensive therapies; data not shown). Looking at the different *TP53* mutation classes, patients with any *TP53^{NMIS}* mutation

face significant early mortality. Two prior studies[25, 26] evaluating MDS demonstrated worse OS

with *TP53*[NMIS] mutations compared to *TP53*[MIS] with the latter looking at post-transplant survival.

However, an AML study from the German-Austrian AMLSG however did not find any impact on

OS based on mutation class (but with a trend towards worse event-free survival with *TP53*[NMIS])

in a cohort treated primarily with intensive chemotherapy.[27] In our cohort, *TP53* splice junction

mutations were associated with the worst outcomes compared to all other mutations. While they

occurred much more frequently in men without any impact on CR1 rates, their adverse impact

on survival was much more pronounced in women. These findings are congruent with recent

demonstration of gender specific differences in the frequencies of AML-associated genetic

alterations and less frequent complex karyotype and mutation in genes related to the

spliceosome machinery in women (including *U2AF1* and *SRSF2*).[28]

On the other hand, the predictive relevance of autosomal monosomies is quite remarkable and

admittedly somewhat surprising in our high-risk cohort with complex karyotype. While it has long

been known that monosomal karyotype is adverse and often enriched in complex karyotype

AMLs[4, 29] with frequent del(17p)[30], these cohorts comprised a heterogeneous mix of AML

patients of all risk groups without specifically focusing on *TP53*-mutated individuals. Considering

the high frequency of complex karyotype in our cohort, we restricted the analysis to

monosomies only while ignoring structural alterations which were near-universal. Importantly,

monosomy 7 was more relevant than monosomy involving chromosomes 5 or 17. We observed

that the predictive value of 2+ monosomies for inferior CR1 was restricted only to the subgroup

receiving non-intensive therapies underscoring its relevance in an increasingly HMA-treated

elderly cohort.

In the context of the *EPI6* signature, *CUX1* emerged as the most pivotal gene. While previous

studies[31, 32] have highlighted the detrimental effects of *CUX1* deletions and mutations in AML,

their significance in *TP53*[MUT] MN has not been evaluated. Notably, in our cohort, *CUX1* losses

(which were more prevalent than mutations) were observed in 10% of cases. These losses

identified a subgroup with an abysmal response rate (0%) to frontline treatment with significantly

worse 2-year survival (**Figure 4A**) particularly among female patients. It is important to

emphasize that while *CUX1* alterations frequently co-occurred with losses of chromosome

7/7q[33], isolated losses at this genomic locus were still associated with adverse clinical

outcomes, underscoring their independent relevance beyond karyotypically detectable -7/7q.

Our observations of *RAS* pathway co-alterations (*CBL*, and *KRAS*) in the *EPI6* signature aligns

with the documented activation of this pathway in *CUX1*-altered MNs, as recently demonstrated

in the context of 7q alterations in myeloid neoplasms.[34]

We note as well that blast counts are irrelevant once there are more than 9% blasts, affirming

that MDS/AML and AML with *TP53*[MUT] are indeed a single biologic entity. That said, establishing

a diagnosis of 'morphologic leukemia-free state (MLFS)' based on blast counts however is

particularly problematic in *TP53*[MUT] MN where significant erythroid-predominant leukemic

hematopoiesis (often CD34-/strong p53+) is frequent. Post-therapy marrow biopsies frequently

show less than 5% CD34-expressing blasts with a significant component of strong p53-

expressing erythroid component (frequently corresponding to a mutation) highlighting that

neither blast count nor CD34 are good surrogates for pathologic CR or MLFS in *TP53*[MUT] MNs.

To this end, the fast turnaround time of IHC compared to all the other tests (NGS, and

karyotype) makes it an attractive surrogate for most if not all non-truncating *TP53* mutations[35],

particularly in elderly AMLs and therapy-related AMLs at diagnosis and after therapy.

A few limitations of our study that merit acknowledgement include: **1]** Lack of molecular MRD in

response assessment **2]** Development of the proposed score using patients treated

heterogeneously with chemotherapy and non-intensive regimens **3]** Use of an MDS (as

opposed to AML) validation cohort. To the last point, most published AML and MDS cohort lack

public data on alterations (especially losses) at the *CUX1* locus hampering their use as a

validation cohort for the *EPI6* signature. Lastly, we were unable to ascertain if some of the

observed *TP53* mutations in patients with low VAF merely corresponded to age-related clonal

hematopoiesis-associated mutations unrelated to the main clone (see **supplementary figure**

10 for analysis of the missense *TP53* substitutions and *TP53* domain relevance in the University

of Chicago cohort). Importantly, our work underscores that not all classes of *TP53* mutations are

equal given the adverse outcomes with splice junction mutations and early mortality with any

TP53^{NMIS} mutations.

In the real-world setting, all candidate components of the proposed risk score (NGS, FISH,

karyotype) are typically available within two weeks of diagnosis. Furthermore, most candidate

genes of *EPI6* are common genes included in standard NGS panels, except perhaps *CUX1*, for

which we recommend an algorithm in the NGS pipeline for calling *CUX1* loss detection. Patients

with *TP53*RS0/Favorable risk are most likely to respond significantly to standard therapies and

have the best chance at alloSCT with durable post-transplant survival. However, most other

patients in *TP53*RS1 and *TP53*RS2/unfavorable groups still face early mortality due to

comorbidities, active second malignancies or treatment-emergent adverse effects including

neutropenic sepsis (especially with venetoclax). As a result, this group has little to no benefit

with existing therapies, highlighting the need for the developing novel agents with better safety

and efficacy profiles for this subgroup.

In conclusion, several novel proposed pre-therapy biologic predictors (*CUX1* deletions, allelic

state, *TP53* splice junction mutations, *TP53* VAF, autosomal monosomies, and specific co-

mutation patterns) have prognostic utility and will better inform response and best candidates for

alloSCT in this high-risk, elderly cohort.

Acknowledgements: Benjamin L. Ebert, Harvard Medical School, for helpful insights related to
biology aspects (CHIP) in email discussions. Esha Patil, undergraduate at University of Illinois,
Urbana-Champaign for pre-processing karyotypes prior to parsing with *R::CytoGPS*. Clyde B.
Schecter, Nicholas Cox and other members of Statalist for their statistical input (related to data
management and analysis) at several time points. Drs. James Vardiman, and Elizabeth Hyjek
who were involved in pathologic diagnosis of several earlier cases from University of Chicago
included in the study.

Prior presentation: Portions of these data were presented as an oral presentation as the
annual meeting of the United State Canadian Academy of Pathology meeting in 2023 held in
New Orlean, LA, USA with another upcoming moderated presentation in the upcoming 2024
USCAP meeting in Baltimore, MD, USA.

Prior peer review: Peer reviewers of *Blood* for an earlier version of the study submitted to
Blood including 207 patients. Most comments/criticisms raised are incorporated/addressed in
the current version with a larger cohort size.

Authorship information: A.K. and A.E.R performed chart review, curated mutations and edited
manuscript. P.M.S., and K.K. performed chart review. E.S. performed chart review and collated
scripts for figures and manuscript. H.V.S. Visiting pathologist curated data from IARC and
EAP53 server. S-Y.Y collated all mutations for lollipop plot generation, B.A., M.S., J.L.P, A.B P.
and M.P.M. contributed cases, did chart review and mutation curation of contributed cases. M.T,
J.S. & P.Wang curated mutation data and examined pipeline for NGS data. A.L. and C.F.
reviewed cytogenetic data. A.P., M.W.D., C.S. & J.E.C, T.K., provided patient care, accrued
patients on clinical trials (HMA/Magrolimab, Gilead), designed some analyses, and edited the
manuscript. M.E.M reviewed the data related to *CUX1* biology and edited those portions of the
manuscript. L.W., E.H., D.A., J.X.C, S.G., S.B.G, and G.V. reviewed pathology data and edited
final version of manuscript. O.L. and P.K. analyzed the *TP53* missense mutations in the
University of Chicago subset reported in the supplementary data. P.Wanjari. & P.W. analyzed
the CNA data. G.V. initiated, designed, supervised study, conducted all statistical analysis, &
wrote the manuscript. All authors edited the manuscript.

COI Disclosure(s): The authors do not have any COI disclosures

REFERENCES

1.   Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791-7.

2.   Breems DA, Lowenberg B. Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum. Haematologica. 2011;96(4):491-3.

3.   Kayser S, Zucknick M, Dohner K, et al. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood. 2012;119(2):551-8.

4.   Rucker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119(9):2114-21.

5.   Grob T, Al Hinai ASA, Sanders MA, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022;139(15):2347-54.

6.   Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200-28.

7.   Weinberg OK, Porwit A, Orazi A, et al. The International Consensus Classification of acute myeloid leukemia. Virchows Arch. 2022.

8.   Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703-19.

9.   Dohner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-77.

10.   Badar T, Atallah E, Shallis R, et al. Survival of TP53-mutated acute myeloid leukemia

patients receiving allogeneic stem cell transplantation after first induction or salvage therapy:

results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Leukemia. 2023;37(4):799-806.

11.   Cluzeau T, Sebert M, Rahme R, et al. Eprenetapopt Plus Azacitidine in TP53-Mutated

Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe

Francophone des Myelodysplasies (GFM). J Clin Oncol. 2021;39(14):1575-83.

12.   Nawas MT, Kosuri S. Utility or Futility? A Contemporary Approach to Allogeneic

Hematopoietic Cell Transplant in TP53-Mutated MDS and AML. Blood Adv. 2023.

13.   Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults:

2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-47.

14.   Katsonis P, Lichtarge O. A formal perturbation equation between genotype and

phenotype determines the Evolutionary Action of protein-coding variations on fitness. Genome

Res. 2014;24(12):2050-8.

15.   Cox DR. Regression Models and Life-Tables. J R Stat Soc B. 1972;34(2):187-+.

16.   Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds

models for censored survival data, with application to prognostic modelling and estimation of

treatment effects. Stat Med. 2002;21(15):2175-97.

17.   Short NJ, Montalban-Bravo G, Hwang H, et al. Prognostic and therapeutic impacts of

mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv.

2020;4(22):5681-9.

18.   Venugopal S, Shoukier M, Konopleva M, et al. Outcomes in patients with newly

diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.

Cancer. 2021;127(19):3541-51.

19.   Pollyea DA, Pratz KW, Wei AH, et al. Outcomes in Patients with Poor-Risk Cytogenetics

with or without TP53 Mutations Treated with Venetoclax and Azacitidine. Clin Cancer Res.

2022;28(24):5272-9.

20.   Badar T AE, Shallis RM, Litzow, RM. Comparable Survival of Treatment Naïve TP53

Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to

Hypomethylating Agent Plus Venetoclax Based Therapy.   Annual Meeting & Exposition;

Sunday, December 10, 2023; San Diego, CA: American Society of Hematology; 2023.

21.   Badar T, Nanaa A, Atallah E, et al. Comparing venetoclax in combination with

hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-

mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and

Neoplastic Diseases (COMMAND). Blood Cancer J. 2024;14(1):32.

22.   Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome

stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med.

2020;26(10):1549-56.

23.   Bahaj W, Kewan T, Gurnari C, et al. Novel scheme for defining the clinical implications

of TP53 mutations in myeloid neoplasia. J Hematol Oncol. 2023;16(1):91.

24.   Shah MV, Tran ENH, Shah S, et al. TP53 mutation variant allele frequency of >/=10% is

associated with poor prognosis in therapy-related myeloid neoplasms. Blood Cancer J.

2023;13(1):51.

25.   Haase D, Stevenson KE, Neuberg D, et al. TP53 mutation status divides

myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Leukemia. 2019;33(7):1747-58.

26.   Lindsley RC, Saber W, Mar BG, et al. Prognostic Mutations in Myelodysplastic

Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017;376(6):536-47.

27.   Boettcher S, Miller PG, Sharma R, et al. A dominant-negative effect drives selection of

TP53 missense mutations in myeloid malignancies. Science. 2019;365(6453):599-604.

28.   Ozga M, Nicolet D, Mrozek K, et al. Sex-associated differences in frequencies and

prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance,

AMLCG). Leukemia. 2023.

29.   Jang JE, Min YH, Yoon J, et al. Single monosomy as a relatively better survival factor in

acute myeloid leukemia patients with monosomal karyotype. Blood Cancer J. 2015;5(10):e358.

30.   Gaillard JB, Chiesa J, Reboul D, et al. Monosomal karyotype routinely defines a poor

prognosis subgroup in acute myeloid leukemia and is frequently associated with TP53 deletion.

Leuk Lymphoma. 2012;53(2):336-7.

31.   Schwartz JR, Ma J, Lamprecht T, et al. The genomic landscape of pediatric

myelodysplastic syndromes. Nat Commun. 2017;8(1):1557.

32.   Aly M, Ramdzan ZM, Nagata Y, et al. Distinct clinical and biological implications of

CUX1 in myeloid neoplasms. Blood Adv. 2019;3(14):2164-78.

33.   Jotte MRM, McNerney ME. The significance of CUX1 and chromosome 7 in myeloid

malignancies. Curr Opin Hematol. 2022;29(2):92-102.

34.   An N, Khan S, Imgruet MK, et al. Oncogenic RAS promotes leukemic transformation of

CUX1-deficient cells. Oncogene. 2023;42(12):881-93.

35.   Tashakori M, Kadia T, Loghavi S, et al. TP53 copy number and protein expression

inform mutation status across risk categories in acute myeloid leukemia. Blood. 2022;140(1):58-

72.

36.   Abrams ZB, Tally DG, Abruzzo LV, et al. RCytoGPS: an R package for reading and

visualizing cytogenetics data. Bioinformatics. 2021;37(23):4589-90.

Figure and Table legends

Figure 1: Ideogram of global losses (orange) and gains (green) across the genome. Recurrent losses are enriched in chromosomes 5, 7 and 17. Furthermore, we observed additional recurrent losses on 12p, besides 16q, 18p, and 18q. Chromosomal gains were prevalent, particularly on chromosomes 8 (trisomy 8), as well as on chromosomes 1, 9, 11, 21, and 22. Clean karyotypes were batched parsed in CytoGPS to create .json files with loss, gain & fusion information. These files were examined using the RCytoGPS package for R, treating them as a binary matrix, to create the ideogram.[36]

Figure 2: Co-mutations and structural alterations in patients with any co-mutations. Only variants occurring at least twice within the cohort are represented. Notably, structural alterations/losses were common with certain genes, particularly *CUX1*, *EZH2*, and *APC*.

Figure 3: Univariable K-M plots of key pre-therapy adverse predictors. A. Antecedent myeloid neoplasm, **B.** Autosomal monosomies and **D.** Highest *TP53* VAF ≥ 25%, all adversely impact overall survival (OS24). **C.** *TP53* splice junction mutations were significantly associated with male gender and were associated with worse survival compared to all other classes of *TP53* mutations.

Figure 4: Univariable adverse impact of *EPI6* genes and outcome. A. Forest plot of the hazard ratios of each of the seven "*EPI6*" genes in the OS24 analysis with numbers and frequencies of occurrence depicted on the right. There were gender specific differences in some of the genes and hence these genes were included in the *EPI6* signature despite borderline adverse significance in the combined analysis. **B.** Patient carrying co-mutations/alterations in any of the 7 "*EPI6*" genes including *CBL*, *CUX1*, *EZH2*, *TET2*, *KRAS*, or *U2AF1* experienced shorter median and overall survival. *CUX1* was the most influential gene in the *EPI6* signature with overall survival of *CUX1*-altered individuals approaching 0% by 12 months after diagnosis.

Figure 5: Impact of *TP53* risk score with relevant predictors on OS24 by flexible parametric analysis. A. Entire cohort analysis separates three prognostic groups corresponding to *TP53*RS scores of 0, 1, 2. **B.** Sensitivity analysis restricting to cases to single center with uniform NGS testing methodology. The *TP53*RS retained its predictive power in this analysis as well.

Table 1: Baseline characteristics of all patients at diagnosis of $TP53^{MUT}$ Myeloid Neoplasm.

Table 2: Multivariable models fitted incorporating the four relevant pretherapy predictors adjusted for age at diagnosis and a clustered sandwich estimator for standard errors accounting for clustering across contributing centers. Except $TP53^{sjm}$ and antecedent treated myeloid neoplasm, all other biologic predictors (*TP53* VAF, 2+ monosomies and *EPI6*) were relevant in the regular Cox P-H model as well as 45-day landmark while monosomies lost their relevance in the competing risk model for leukemia-specific OS24. Only *TP53* VAF and *EPI6* remained relevant in all three models.

Figures and Tables-low resolution

Figure 1: Ideogram of global losses (orange) and gains (green) across the genome.

Figure 2: Co-mutations and structural alterations in patients with any co-mutations.

Figure 3: Univariable K-M plots of key pre-therapy adverse predictors.

Figure 4: Univariable adverse impact of *EPI6* genes and outcome.

A

B

Figure 5: Impact of *TP53* risk score with relevant predictors on OS24 by flexible parametric analysis.

Table 1: Baseline characteristics of all 234 patients at diagnosis of $TP53^{MUT}$ Myeloid Neoplasm stratified by *TP53* allelic state at diagnosis (see methods section for definition of allelic state).

	$TP53^{SH}$ N=66 (28.2%)	$TP53^{MH}$ N=168 (71.8%)	Test
Age at diagnosis, Median [IQR]			
Age (years)	68.0 [14-89]	68.0 [23-93]	0.453
Baseline labs, Median [IQR]			
Hemoglobin (g/dL)	8.2 [3-13]	8.0 [4-17]	0.693
Platelet Count (10□/L)	51.0 [5-344]	40.5 [5-585]	0.779
Abs. Neutrophil Count (10□/L)	0.6 [0-5200]	0.7 [0-8740]	0.569
Sex			
Male	32 (48.5%)	100 (59.5%)	0.125
Female	34 (51.5%)	68 (40.5%)	
Era of dx.-no.(%)			
Pre-2018	19 (28.8%)	43 (25.6%)	0.618
2018-current	47 (71.2%)	125 (74.4%)	
Prior Treated Myeloid Neoplasm*-no.(%)			
No	53 (80.3%)	136 (81.0%)	0.910
Yes	13 (19.7%)	32 (19.0%)	
MDS/AML-ICC 2022			
MDS/AML (10-19% blasts)	11 (16.9%)	35 (20.8%)	0.501
AML (20%+ blasts)	54 (83.1%)	133 (79.2%)	
Complex karyotype			
Absent	21 (38.2%)	19 (12.3%)	<0.001
Present	34 (61.8%)	136 (87.7%)	
Chromosome 7 loss			
Absent	30 (53.6%)	72 (45.6%)	0.303
Present	26 (46.4%)	86 (54.4%)	
Monosomies-no.(%)			
0-1 Monosomy	32 (58.2%)	47 (30.3%)	<0.001
2+ Monosomies	23 (41.8%)	108 (69.7%)	
Chromosome 12(p) loss			
del(12p) absent	62 (93.9%)	138 (82.1%)	0.021
del(12p) present	4 (6.1%)	30 (17.9%)	
***TP53* mutation class‡-no.(%)**			
Missense	47 (71.2%)	106 (63.1%)	0.240
Non-Missense	19 (28.8%)	62 (36.9%)	
Germline alteration.-no.(%)			
Absent	20 (76.9%)	46 (86.8%)	0.266
Present	6 (23.1%)	7 (13.2%)	
Co-alterations-no.(%)			
Absent	28 (42.4%)	60 (35.7%)	0.340
Present	38 (57.6%)	108 (64.3%)	
Therapies-no.(%)			
Low-inten. (HMA±VEN)	40 (63.5%)	101 (62.0%)	0.815
Intensive (Chemo)	14 (22.2%)	37 (22.7%)	

Best.Supp.Care	7 (11.1%)	15 (9.2%)	
CPX-351/Vyxeos	2 (3.2%)	10 (6.1%)	
Resp. frontline†-no.(%)			
No CR/CRi	30 (54.5%)	108 (80.0%)	<0.001
CR/CRi	25 (45.5%)	27 (20.0%)	

Med., Median; IQR, Interquartile range; BSC, Best Supportive Care; CR, Complete Response; CRi, CR & incomplete hematologic recovery

*These included treated or untreated MDS (Low and High-risk), MDS/MPN and MPN without any $TP53^{MUT}$ up until evolution/progression to a $TP53^{MUT}$ myeloid neoplasm.

†Numbers reported in therapies and response may not add up to cohort total since some patients were either untreated or if treated, response could not evaluated due to various reasons (active second malignancy, early treatment-emergent adverse effects, transferred care elsewhere or early mortality)

‡In pts with multiple mutations, case was designated $TP53^{NMIS}$ if ≥1 *TP53* mutation was a $TP53^{NMIS}$ mutation.

Table 2: Multivariable models fitted incorporating the four relevant covariates adjusted for age at diagnosis.

| | 45-day landmark | | | | | |
| | Cox | | Cox | | Compet. Risk | |
	HR	95% CI	HR	95% CI	HR	95% CI
Age at dx.						
≤70 yrs	1.00		1.00		1.00	
>70 yrs	1.35***	[1.09, 1.68]	1.45***	[1.19, 1.78]	1.24*	[0.97, 1.59]
Anteced. Treated MN						
No	1.00		1.00		1.00	
Yes	1.78*	[0.93, 3.40]	2.01*	[0.89, 4.52]	1.51	[0.81, 2.81]
***TP53* Splice Mutn.**						
Absent	1.00		1.00		1.00	
Present	1.72	[0.89, 3.32]	1.71	[0.88, 3.33]	1.77	[0.80, 3.94]
Highest *TP53* VAF						
≤25%	1.00		1.00		1.00	
>25%	1.78***	[1.39, 2.27]	1.62***	[1.33, 1.96]	1.39***	[1.09, 1.77]
Monosomies						
0-1 monosomy	1.00		1.00		1.00	
2+ monosomies	1.55***	[1.17, 2.07]	1.55***	[1.15, 2.08]	1.27	[0.83, 1.95]
***EPI6* signature**						
Absent	1.00		1.00		1.00	
Present	1.88***	[1.40, 2.53]	1.84***	[1.49, 2.26]	1.45***	[1.18, 1.78]

Hazard ratio (HR) for competing risk model denotes Sub-Hazard Ratio

*** p<.01, ** p<.05, * p<.1